Auris Medical Holding (EARS) Reports Positive Results from Second Phase 1 Clinical Trial with Intranasal Betahistine
Tweet Send to a Friend
Auris Medical Holding AG (NASDAQ: EARS) today announced positive results from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
